Chemotherapy use, performance status, and quality of life at the end of life

JAMA Oncology

Volumn 1, Issue 6, 2015, Pages 778-784

  Prigerson, Holly G ^a,b   Bao, Yuhua ^b   Shah, Manish A ^b   Elizabeth Paulk, M ^d   LeBlanc, Thomas W ^c   Schneider, Bryan J ^e   Garrido, Melissa M ^f,g   Carrington Reid, M ^b   Berlin, David A ^h   Adelson, Kerin B ^k   Neugut, Alfred I ^i,j   MacIejewski, Paul K ^a,b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h WEILL CORNELL MEDICAL CENTER   (United States)

ⁱ New York Presbyterian Hospital Weill Cornell Center ^*  (United States)

^j Columbia University ^*  (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; CANCER STAGING; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; FEMALE; HEALTH STATUS; HEALTH STATUS INDICATOR; HUMAN; LONGITUDINAL STUDY; MALE; MENTAL STRESS; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEOPLASMS; ODDS RATIO; PALLIATIVE THERAPY; PATHOLOGY; PATIENT SELECTION; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TERMINAL CARE; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; ODDS RATIO; PALLIATIVE CARE; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; STRESS, PSYCHOLOGICAL; SURVEYS AND QUESTIONNAIRES; TERMINAL CARE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 85010919189     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.2378     Document Type: Article

References (31)

1. Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol. 2014;15 (3):e112-e118. doi:10.1016/S1470-2045(13)70578-3. Published online February 14, 2014.
2. Meier DE. 'I don't want Jenny to think I'm abandoning her': views on overtreatment. Health Aff (Millwood). 2014;33(5):895-898.
3. Bach PB. The day I started lying to Ruth. 2014. http://nymag.com/news/features/cancer-peter-bach-2014-5/. Accessed June 10, 2015
4. Braga S. Why do our patients get chemotherapy until the end of life? Ann Oncol. 2011;22(11): 2345-2348.
5. Anders CK, Peppercorn J. Treating in the dark: unanswered questions on costs and benefits of late line therapy for metastatic breast cancer. Cancer Invest. 2009;27(1):13-16.
6. Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715-1724.
7. Eastern Cooperative Oncology Group. ECOG performance status. http://ecog-acrin.org/resources/ecog-performance-status. Acessed June 3, 2015.
8. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980;65(1):25-32.
9. Pater JL, Loeb M. Nonanatomic prognostic factors in carcinoma of the lung: a multivariate analysis. Cancer. 1982;50(2):326-331.
10. Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG. Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ. 2014;348:g1219. doi:10.1136/bmj.g1219.
11. Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS. Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med. 2003;138(8):639-643.
12. Salloum RG, Smith TJ, Jensen GA, Lafata JE. Survival among non-small cell lung cancer patients with poor performance status after first line chemotherapy. Lung Cancer. 2012;77(3): 545-549.
13. Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer. 2003;39(1):55-61.
14. Anshushaug M, Gynnild MA, Kaasa S, Kvikstad A, Grønberg BH. Characterization of patients receiving palliative chemo-and radiotherapy during end of life at a regional cancer center in Norway. Acta Oncol. 2015;54(3):395-402.
15. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005;23(24):5542-5551.
16. Cortes J, O'Shaughnessy J, Loesch D, et al; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377 (9769):914-923.
17. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004;40(4):536-542.
18. Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9(1):29-33.
19. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc. 1975;23 (10):433-441.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
21. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6): 649-655.
22. Zhang B, Nilsson ME, Prigerson HG. Factors important to patients' quality of life at the end of life. Arch Intern Med. 2012;172(15):1133-1142.
23. Abbott CH, Prigerson HG, Maciejewski PK. The influence of patients' quality of life at the end of life on bereaved caregivers' suicidal ideation. J Pain Symptom Manage. 2014;48(3):459-464.
24. Greer JA, Pirl WF, Jackson VA, et al. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol. 2012;30(4): 394-400.
25. Teno JM, Gozalo PL, Bynum JP, et al. Change in end-of-life care for Medicare beneficiaries: site of death, place of care, and health care transitions in 2000, 2005, and 2009. JAMA. 2013;309(5): 470-477.
26. Institute of Medicine. Dying in America: Improving Quality and Honoring Individual Preferences Near the End of Life. Washington, DC: The National Academies Press; 2014.
27. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004; 22(2):315-321.
28. Saito AM, Landrum MB, Neville BA, Ayanian JZ, Earle CC. The effect on survival of continuing chemotherapy to near death. BMC Palliat Care. 2011;10:14.
29. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290(12):1624-1632.
30. Bach PB, Schrag D, Begg CB. Resurrecting treatment histories of dead patients: a study design that should be laid to rest. JAMA. 2004;292(22): 2765-2770.
31. Lamont EB, Schilsky RL, He Y, et al; Alliance for Clinical Trials in Oncology. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst. 2015;107(1):336.